热门资讯> 正文
Kazia Therapeutics出售Cantrixil的知识产权和商标权
2025-03-31 19:55
- Kazia Therapeutics (NASDAQ:KZIA) announced on Monday the sale of all intellectual property and trademarks rights to Cantrixil for USD $1M.
- In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics.
- Having decided not to pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantrixil preclinically for the treatment of hematological cancers.
More on Kazia
- Kazia Therapeutics announces $2M registered direct offering
- Kazia says glioblastoma trial data won’t support FDA accelerated nod for lead drug
- Seeking Alpha’s Quant Rating on Kazia
- Historical earnings data for Kazia
- Financial information for Kazia
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
